KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 0.35.

  • Jazz Pharmaceuticals' Equity Ratio rose 243.22% to 0.35 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35, marking a year-over-year increase of 243.22%. This contributed to the annual value of 0.34 for FY2024, which is 390.26% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Equity Ratio is 0.35, which was up 243.22% from 0.34 recorded in Q2 2025.
  • Jazz Pharmaceuticals' Equity Ratio's 5-year high stood at 0.56 during Q1 2021, with a 5-year trough of 0.26 in Q3 2022.
  • In the last 5 years, Jazz Pharmaceuticals' Equity Ratio had a median value of 0.32 in 2021 and averaged 0.33.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Equity Ratio tumbled by 4545.07% in 2022, and later skyrocketed by 1781.25% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Equity Ratio stood at 0.32 in 2021, then decreased by 11.67% to 0.28 in 2022, then rose by 15.17% to 0.33 in 2023, then increased by 3.9% to 0.34 in 2024, then rose by 2.29% to 0.35 in 2025.
  • Its last three reported values are 0.35 in Q3 2025, 0.34 for Q2 2025, and 0.36 during Q1 2025.